| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2990.2002.T01-2-00427.X |
| P698 | PubMed publication ID | 12445159 |
| P2093 | author name string | Green AJ | |
| P2860 | cites work | Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine | Q24322674 |
| Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding | Q27619633 | ||
| Signaling through scaffold, anchoring, and adaptor proteins | Q28131792 | ||
| A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid | Q28207898 | ||
| Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease | Q28241772 | ||
| Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein | Q28260479 | ||
| Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial | Q28343193 | ||
| Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease | Q28366081 | ||
| Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease | Q28910345 | ||
| 14-3-3 proteins: structure, function, and regulation | Q29619100 | ||
| Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease | Q33933969 | ||
| Presenilin, Notch, and the genesis and treatment of Alzheimer's disease | Q33944227 | ||
| Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene | Q34303468 | ||
| The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease | Q34321510 | ||
| Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid | Q57274061 | ||
| Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease | Q57781094 | ||
| Increased cerebrospinal fluid tau in patients with Alzheimer's disease | Q72303120 | ||
| 14-3-3 alpha and delta are the phosphorylated forms of raf-activating 14-3-3 beta and zeta. In vivo stoichiometric phosphorylation in brain at a Ser-Pro-Glu-Lys MOTIF | Q72631513 | ||
| Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment | Q73039702 | ||
| Increased cerebrospinal fluid protein tau concentration in neuro-AIDS | Q73226664 | ||
| Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology | Q73551190 | ||
| Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease | Q73556105 | ||
| Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice | Q73632001 | ||
| New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests | Q73742650 | ||
| Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies | Q73766489 | ||
| Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid | Q73838678 | ||
| 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease | Q74587325 | ||
| Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease | Q74614409 | ||
| Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression | Q77351145 | ||
| Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies | Q77738553 | ||
| A new variant of Creutzfeldt-Jakob disease in the UK. | Q34374893 | ||
| Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. | Q34403513 | ||
| A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group | Q34744744 | ||
| 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins | Q35624026 | ||
| Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay | Q35788903 | ||
| Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets | Q36978208 | ||
| The toxicity in vitro of beta-amyloid protein | Q40422520 | ||
| Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study | Q40969218 | ||
| Amyloid beta-peptide is produced by cultured cells during normal metabolism | Q41602809 | ||
| New variant Creutzfeldt-Jakob disease: psychiatric features | Q41604119 | ||
| Cerebrospinal fluid tau protein as a potential diagnostic marker in Alzheimer's disease | Q41748084 | ||
| Both total and phosphorylated tau are increased in Alzheimer's disease | Q41765446 | ||
| Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms | Q42468356 | ||
| Up-regulation of system A activity in the regenerating rat liver. | Q42506577 | ||
| Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease | Q43592525 | ||
| Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease | Q43708035 | ||
| Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease | Q43863115 | ||
| 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein | Q43975864 | ||
| Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent | Q44592404 | ||
| High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. | Q45192211 | ||
| Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease | Q46611463 | ||
| Clinical-neuropathological correlations in Alzheimer's disease and related dementias | Q46927555 | ||
| Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease | Q47692868 | ||
| Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease | Q48127489 | ||
| Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. | Q48280212 | ||
| Effects of PS1 deficiency on membrane protein trafficking in neurons | Q48327056 | ||
| Tau protein pathology in neurodegenerative diseases | Q48368290 | ||
| Increased CSF tau protein in corticobasal degeneration | Q48545187 | ||
| Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease | Q48891427 | ||
| The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies | Q48913771 | ||
| Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization | Q49169032 | ||
| Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. | Q50959210 | ||
| Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. | Q51980704 | ||
| Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. | Q52029709 | ||
| Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. | Q53202087 | ||
| Cerebrospinal protein tau is elevated in early Alzheimer's disease. | Q53213849 | ||
| Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. | Q53218972 | ||
| Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. | Q53224188 | ||
| No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. | Q53225650 | ||
| Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. | Q53229335 | ||
| Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. | Q53238052 | ||
| A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. | Q53239126 | ||
| Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. | Q53313124 | ||
| Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. | Q53339552 | ||
| Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. | Q53341838 | ||
| A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. | Q53341841 | ||
| Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. | Q54359584 | ||
| 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. | Q55475265 | ||
| Current clinical diagnosis in Creutzfeldt-Jakob disease: Identification of uncommon variants | Q57274037 | ||
| S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease | Q57274052 | ||
| P433 | issue | 6 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| cerebrospinal fluid | Q54196 | ||
| P304 | page(s) | 427-440 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Neuropathology and Applied Neurobiology | Q7002494 |
| P1476 | title | Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease | |
| P478 | volume | 28 |
| Q46752254 | Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain |
| Q37372476 | Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma |
| Q37061036 | Creutzfeldt-Jakob disease: case discussion and imaging review |
| Q35787179 | Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. |
| Q48445053 | Neurocognitive disorders: cluster 1 of the proposed meta-structure for DSM-V and ICD-11. |
| Q51930123 | Proteomic analysis of the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. |
Search more.